SelPac

Trial description
A Randomised three-arm, open label, Phase II study of continuous Selumetinib versus continuous or interrupted Selumetinib in combination with weekly Paclitaxel in Metastatic Uveal Melanoma
Contact name
Dr Pippa Corrie
Trial start date
Saturday, August 1, 2015
Trial end date
Saturday, March 2, 2019
Trial tumour type
Skin & melanoma
Show on Radiotherapy
No